Hims and Hers Health Inc. soared in pre-market trading after Novo Nordisk A/S said it would sell its popular weight-loss drug ...

The companies announced a long-term collaboration to make obesity treatments more affordable, they said on Tuesday.

Him & Hers Health and Novo Nordisk are collaborating to offer weight-loss treatment, including access to Wegovy along with ...

But recent weak U.S. prescription data is leading some investors and analysts to question whether that stellar run, which ...

Telehealth providers will soon offer more affordable access to weight loss drug Wegovy, according to manufacturer Novo ...

In a move which could shake up the diabetes market, Novo Nordisk is discontinuing the country’s largest selling insulin, ...

Novo Nordisk appears to be letting compounded GLP-1 bygones be bygones—at least, in one respect. | Novo Nordisk appears to be ...

Novo Nordisk has teamed up with Hims & Hers Health, LifeMD and Ro for cash-paying patients to access Wegovy injection 2.4 mg ...

Novo Nordisk will continue offering its top-selling insulin brand, Mixtard, in vial form in India, despite phasing out ...

Shares of Hims & Hers Health (NYSE: HIMS) and LifeMD (NASDAQ: LFMD) are surging on Tuesday. Shares soared after pharma giant ...

A judge denied compounders' request to keep making off-brand Wegovy and Ozempic after the FDA removed semaglutide from its shortage list.

Novo Nordisk's booming obesity drugs & diabetes portfolio make it a top growth play. Click here to read an analysis of NVO ...